Neurocrine Biosciences Q2 2024 Adj. EPS $1.63 Beats $1.03 Estimate, Sales $590.200M Beat $547.070M Estimate
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences (NASDAQ:NBIX) reported Q2 2024 earnings of $1.63 per share, beating the analyst estimate of $1.03 by 58.25%. Sales were $590.2 million, surpassing the $547.07 million estimate by 7.88%. Both earnings and sales showed significant year-over-year growth.
August 01, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences reported strong Q2 2024 earnings and sales, significantly beating analyst estimates. The EPS of $1.63 was 58.25% higher than the expected $1.03, and sales of $590.2 million exceeded the $547.07 million estimate by 7.88%. Both metrics showed substantial year-over-year growth.
The significant beat on both earnings and sales, along with strong year-over-year growth, is likely to positively impact NBIX's stock price in the short term. Investors typically react favorably to such strong financial performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100